Cholix-derived carriers for oral delivery of heterologous payload
US11324833B2 · kind B2 · utility
2Cited by
59References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 27, 2020 |
| Grant date | May 10, 2022 |
| Priority date | — |
| Expiry date | May 27, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/01
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides delivery constructs comprising a carrier coupled to a heterologous payload, wherein coupling of the carrier to the payload can result in transportation of the payload (e.g., a therapeutic payload) into and/or across intact polarized epithelial cells (e.g., epithelial cells of the gut of a mammal). The delivery construct can be part of a pharmaceutical composition that can be orally administered to a subject to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases or autoimmune diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.